Show simple item record

dc.contributor.authorMartin-Galiano, Antonio Javier 
dc.contributor.authorEscolano-Martínez, María S 
dc.contributor.authorCorsini, Bruno 
dc.contributor.authorde la Campa, Adela G 
dc.contributor.authorYuste, Jose Enrique 
dc.date.accessioned2021-04-19T15:27:14Z
dc.date.available2021-04-19T15:27:14Z
dc.date.issued2021-02-24
dc.identifier.citationVaccines (Basel) . 2021 Feb 24;9(3):187.es_ES
dc.identifier.issn2076-393Xes_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/12689
dc.description.abstractKnowledge-based vaccinology can reveal uncharacterized antigen candidates for a new generation of protein-based anti-pneumococcal vaccines. DiiA, encoded by the sp_1992 locus, is a surface protein containing either one or two repeats of a 37mer N-terminal motif that exhibits low interstrain variability. DiiA belongs to the core proteome, contains several conserved B-cell epitopes, and is associated with colonization and pathogenesis. Immunization with DiiA protein via the intraperitoneal route induced a strong IgG response, including different IgG subtypes. Vaccination with DiiA increased bacterial clearance and induced protection against sepsis, conferring 70% increased survival at 48 h post-infection when compared to the adjuvant control. The immunogenic response and survival rates in mice immunized with a truncated DiiA version lacking 119 N-terminal residues were remarkably lower, confirming the relevance of the repeat zone in the immunoprotection by DiiA. Intranasal immunization of mice with the entire recombinant protein elicited mucosal IgG and IgA responses that reduced bacterial colonization of the nasopharynx, confirming that this protein might be a vaccine candidate for reducing the carrier rate. DiiA constitutes an example of how functionally unannotated proteins may still represent promising candidates that can be used in prophylactic strategies against the pneumococcal carrier state and invasive disease.es_ES
dc.description.sponsorshipThis research was funded by Ministerio de Economía y Competitividad (grant numbers SAF2017-83388 and BIO2017-82951-R) and Instituto de Salud Carlos III (grant number MPY 509/19).es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relation.isversionofPublisher's versiones_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/*
dc.subjectDiiAes_ES
dc.subjectSPD_1789es_ES
dc.subjectSpr1806.es_ES
dc.subjectStreptococcus pneumoniaees_ES
dc.subjectcarrier statees_ES
dc.subjecthypothetical proteines_ES
dc.subjectprotein vaccinees_ES
dc.subjectreverse vaccinologyes_ES
dc.subjectsepsises_ES
dc.titleImmunization with SP_1992 (DiiA) Protein of Streptococcus pneumoniae Reduces Nasopharyngeal Colonization and Protects against Invasive Disease in Mice.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución 4.0 Internacional*
dc.identifier.pubmedID33668195es_ES
dc.format.volume9es_ES
dc.format.number3es_ES
dc.identifier.doi10.3390/vaccines9030187es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)es_ES
dc.contributor.funderInstituto de Salud Carlos IIIes_ES
dc.description.peerreviewedes_ES
dc.relation.publisherversionhttps://doi.org/10.3390/vaccines9030187es_ES
dc.identifier.journalVaccineses_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2017-83388es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BIO2017-82951-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/MPY 509/19es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Acceso Abierto
Thumbnail
Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución 4.0 Internacional
This item is licensed under a: Atribución 4.0 Internacional